News

Approvals for a twice-yearly schizophrenia therapy and a seizure drug for infants, a full approval for Keytruda, and a revised EUA for a COVID-19 therapy round out the week.

U.S. hospitals are spending $310 million annually to manage the additional clinical, operational, logistical, and patient care work associated with white and brown bagging requirements, according to a new report.

Almost 21% of adults were uninsured in states that failed to expand Medicaid, compared to about 10% of adults in expansion states.

Three notable medications to treat liver diseases are expected to come online in the third quarter of 2021 and in 2022, according to PBM OptumRx.

A new study gives physicians the power to help patients at risk of obstructive sleep apnea, but it also highlights the relative lack of public attention on prevention.

Almost 95% of U.S. employers surveyed expect to see increased demand for medical services due to employees deferring care because of the pandemic. More than 90% are concerned about their employees’ long-term mental health because of COVID-19, according to a survey of 136 large employers by the Business Group on Health.

Johnson & Johnson’s experimental HIV vaccine, which uses the same technology as its COVID-19 vaccine, was found to not be effective at preventing infection.

A targeted therapy using non-thermal radio waves improved overall survival in hepatocellular carcinoma (HCC) patients and had no side effects, a new study found.

Tecentriq and Keytruda may also be eventually approved as adjuvant therapies.

In this week’s episode of Tuning In to the C-Suite podcast, MHE Associate Editor Briana Contreras interviewed VillageMD’s Senior Medical Director of Village Medical at Home, Dr. Tom Cornwell. Dr. Cornwell discussed the main benefits of primary care at home, which includes the benefit of cost savings for patients, maintaining control of hospital readmissions and others. Dr. Cornwell also noted what has changed in the industry of at-home care and if there has been interest from payers like insurance companies and medicare in the service.

Though the study did not meet its endpoint, the strategy behind it remains under investigation.

Moderna's phase 1 trial of mRNA vaccine against HIV is deigned to enroll 40 patients.

Developers of the drug express disappointment but plan to seek meetings with regulators in hopes of reviving the application.

This opinion piece contributed by Draper voices today's digital platforms can help eliminate the administrative burden on nurses.

The government awarded $80 million in grants to help 60 organizations train more than 1,500 navigators who will focus particularly on underserved communities.

The scientific community has the urgent opportunity to produce more research on the proven health benefits of testosterone and other hormones for women.

The full results from the Emperor-Preserved trial show Jardiance reduces the risk of hospital and death from heart failure.

In this final part of a three-part video series, Briana Contreras, associate editor of MHE, spoke with Dr. Maria Hernandez, founder and CEO of Impact4Health. Maria shared not only how healthcare inequities remain to be an issue and what needs to be addressed, but also the progress that has been made over time through awareness, conversations and laws, especially due to the heightened awareness of inequities caused from the COVID-19 pandemic and the tragic deaths of George Floyd, Breonna Taylor and many more - which have now occurred over a year ago.

Greater uptake of hepatitis C medication may help improve the health of Medicaid enrollees and reduce the economic burden of untreated hepatitis C on the U.S. healthcare system, the authors said.

In this final part of a three-part video series, Managed Healthcare Executive® Managing Editor Peter Wehrwein recently interviewed Kulleni Gebreyes, M.D., director of Deloitte's new Health Equity Institute about her career, healthcare disparities and equity issues and the work of the institute.

The combination bamlanivimab and etesevimab can resume use and distribution to treat mild-to-moderate COVID-19 but only in states where variants resistant to the therapy are low.

The resulting spike in telehealth use exceeded expectations, with an 11,718% increase in remote Medicare visits between March and April 2020.

In this second of a three-part video series, Managed Healthcare Executive® Managing Editor Peter Wehrwein recently interviewed Kulleni Gebreyes, M.D., director of Deloitte's new Health Equity Institute about her career, healthcare disparities and equity issues and the work of the institute.

Tecentriq loses indication, Xarelto is approved for reduce risks of cardiovascular events, Tibsovo is approved for rare cancer, Skytrofa is a new, once-weekly growth hormone, and supplemental application is filed Orencia graft-versus-host disease.

In this first of a three-part video series, Managed Healthcare Executive® Managing Editor Peter Wehrwein recently interviewed Kulleni Gebreyes, M.D., director of Deloitte's new Health Equity Institute about her career, healthcare disparities and equity issues and the work of the institute.

Employees are willing to change jobs to receive better coverage for specialty medications.

Organizations should prepare for massive updates to quality measurement and reimbursement in 2023, while simultaneously addressing cost measurement in 2022.

The update indicates there is a serious risk of dehydration and is contraindicated in children.

Bluebook Rx is a new solution that helps employers and plan sponsors better understand and optimize their prescription drug spending.

In this second part of a three-part video series, Briana Contreras, associate editor of MHE, spoke with Dr. Maria Hernandez, founder and CEO of Impact4Health. Maria shared not only how healthcare inequities remain to be an issue and what needs to be addressed, but also the progress that has been made over time through awareness, conversations and laws, especially due to the heightened awareness of inequities caused from the COVID-19 pandemic and the tragic deaths of George Floyd, Breonna Taylor and many more - which have now occurred over a year ago.